An N-terminal fragment of the prion protein binds to amyloid-β oligomers and inhibits their neurotoxicity in vivo

Journal of Biological Chemistry

Volumn 288, Issue 11, 2013, Pages 7857-7866

  Fluharty, Brian R ^a   Biasini, Emiliano ^a   Stravalaci, Matteo ^b   Sclip, Alessandra ^b   Diomede, Luisa ^b   Balducci, Claudia ^b   La Vitola, Pietro ^b   Messa, Massimo ^b   Colombo, Laura ^b   Forloni, Gianluigi ^b   Borsello, Tiziana ^b   Gobbi, Marco ^b   Harris, David A ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE; CELLULAR PRION PROTEINS; COGNITIVE DEFICITS; HIPPOCAMPAL NEURONS; NEUROTOXIC EFFECTS; POSITIVELY CHARGED; POTENT INHIBITOR; THERAPEUTIC AGENTS;

GLYCOPROTEINS; PEPTIDES; TOXICITY;

OLIGOMERS;

AMYLOID BETA PROTEIN; N1 PEPTIDE; OLIGOMER; PEPTIDE FRAGMENT; PRION PROTEIN; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAENORHABDITIS ELEGANS; CONTROLLED STUDY; DRUG MECHANISM; DRUG PROTEIN BINDING; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; MEMORY DISORDER; MOUSE; NEUROTOXICITY; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN POLYMERIZATION; PROTEIN PROTEIN INTERACTION; RESIDUE ANALYSIS; SEQUENCE ANALYSIS;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOIDOGENIC PROTEINS; ANIMALS; CAENORHABDITIS ELEGANS; HIPPOCAMPUS; MICE; MICE, INBRED C57BL; MODELS, BIOLOGICAL; NEURODEGENERATIVE DISEASES; NEURONS; PEPTIDES; PRIONS; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; SURFACE PLASMON RESONANCE; SYNAPSES; THIAZOLES;

EID: 84875174182     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.423954     Document Type: Article

References (34)

1. Alzheimer's Association (2012) 2012 Alzheimer's disease facts and figures. Alzheimers Dement. 8, 131-168
2. Selkoe, D. J. (2011) Alzheimer's disease. Cold Spring Harb. Perspect. Biol. 3, a004457
3. Selkoe, D. J. (2008) Soluble oligomers of the amyloid β-protein impair synaptic plasticity and behavior. Behav. Brain Res. 192, 106-113
4. Laurén, J., Gimbel, D. A., Nygaard, H. B., Gilbert, J. W., and Strittmatter, S. M. (2009) Cellular prion protein mediates impairment of synaptic plasticity by amyloid-β oligomers. Nature 457, 1128-1132
5. Chen, S., Yadav, S. P., and Surewicz, W. K. (2010) Interaction between human prion protein and amyloid-β (Aβ) oligomers: role of N-terminal residues. J. Biol. Chem. 285, 26377-26383
6. Balducci, C., Beeg, M., Stravalaci, M., Bastone, A., Sclip, A., Biasini, E., Tapella, L., Colombo, L., Manzoni, C., Borsello, T., Chiesa, R., Gobbi, M., Salmona, M., and Forloni, G. (2010) Synthetic amyloid-β oligomers impair long-term memory independently of cellular prion protein. Proc. Natl. Acad. Sci. U.S.A. 107, 2295-2300
7. Gimbel, D. A., Nygaard, H. B., Coffey, E. E., Gunther, E. C., Laurén, J., Gimbel, Z. A., and Strittmatter, S. M. (2010) Memory impairment in transgenic Alzheimer mice requires cellular prion protein. J. Neurosci. 30, 6367-6374
8. Um, J. W., Nygaard, H. B., Heiss, J. K., Kostylev, M. A., Stagi, M., Vortmeyer, A., Wisniewski, T., Gunther, E. C., and Strittmatter, S. M. (2012) Alzheimer amyloid-β oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nat. Neurosci. 15, 1227-1235
9. You, H., Tsutsui, S., Hameed, S., Kannanayakal, T. J., Chen, L., Xia, P., Engbers, J. D., Lipton, S. A., Stys, P. K., and Zamponi, G. W. (2012) Aβ neurotoxicity depends on interactions between copper ions, prion protein, and N-methyl-D-aspartate receptors. Proc. Natl. Acad. Sci. U.S.A. 109, 1737-1742
10. Kudo, W., Lee, H. P., Zou, W. Q., Wang, X., Perry, G., Zhu, X., Smith, M. A., Petersen, R. B., and Lee, H. G. (2012) Cellular prion protein is essential for oligomeric amyloid-β-induced neuronal cell death. Hum. Mol. Genet. 21, 1138-1144
11. Freir, D. B., Nicoll, A. J., Klyubin, I., Panico, S., Mc Donald, J. M., Risse, E., Asante, E. A., Farrow, M. A., Sessions, R. B., Saibil, H. R., Clarke, A. R., Rowan, M. J., Walsh, D. M., and Collinge, J. (2011) Interaction between prion protein and toxic amyloid-β assemblies can be therapeutically targeted at multiple sites. Nat. Commun. 2, 336
12. Barry, A. E., Klyubin, I.,McDonald, J. M., Mably, A. J., Farrell, M. A., Scott, M., Walsh, D. M., and Rowan, M. J. (2011) Alzheimer's disease brainderived Amyloid-β-mediated inhibition of LTP in Vivo is prevented by immunotargeting cellular prion protein. J. Neurosci. 31, 7259-7263
13. Chung, E., Ji, Y., Sun, Y., Kascsak, R. J., Kascsak, R. B., Mehta, P. D., Strittmatter, S. M., and Wisniewski, T. (2010) Anti-PrPC monoclonal antibody infusion as a novel treatment for cognitive deficits in an Alzheimer's disease model mouse. BMC Neurosci. 11, 130
14. Calella, A. M., Farinelli, M., Nuvolone, M., Mirante, O., Moos, R., Falsig, J., Mansuy, I. M., and Aguzzi, A. (2010) Prion protein and Aβ-related synaptic toxicity impairment. EMBO Mol. Med. 2, 306-314
15. Kessels, H. W., Nguyen, L. N., Nabavi, S., and Malinow, R. (2010) The prion protein as a receptor for amyloid-β. Nature 466, E3-E4; discussion E4-E5
16. Cissé, M., Sanchez, P. E., Kim, D. H., Ho, K., Yu, G. Q., and Mucke, L. (2011) Ablation of cellular prion protein does not ameliorate abnormal neural network activity or cognitive dysfunction in the J20 line of human amyloid precursor protein transgenic mice. J. Neurosci. 31, 10427-10431
17. Vincent, B., Paitel, E., Saftig, P., Frobert, Y., Hartmann, D., De Strooper, B., Grassi, J., Lopez-Perez, E., and Checler, F. (2001) The disintegrins ADAM10 and TACE contribute to the constitutive and phorbol esterregulated normal cleavage of the cellular prion protein. J. Biol. Chem. 276, 37743-37746
18. Chen, S. G., Teplow, D. B., Parchi, P., Teller, J. K., Gambetti, P., and Autilio-Gambetti, L. (1995) Truncated forms of the human prion protein in normal brain and in prion diseases. J. Biol. Chem. 270, 19173-19180
19. Harris, D. A., Huber, M. T., van Dijken, P., Shyng, S. L., Chait, B. T., and Wang, R. (1993) Processing of a cellular prion protein: identification of Nand C-terminal cleavage sites. Biochemistry 32, 1009-1016
20. Nieznanski, K., Choi, J. K., Chen, S., Surewicz, K., and Surewicz, W. K. (2012) Soluble prion protein inhibits amyloid-β (Aβ) fibrillization and toxicity. J. Biol. Chem. 287, 33104-33108
21. Zahn, R., von Schroetter, C., and Wüthrich, K. (1997) Human prion proteins expressed in Escherichia coli and purified by high-affinity column refolding. FEBS Lett. 417, 400-404
22. Cissé, M., Halabisky, B., Harris, J., Devidze, N., Dubal, D. B., Sun, B., Orr, A., Lotz, G., Kim, D. H., Hamto, P., Ho, K., Yu, G. Q., and Mucke, L. (2011) Reversing EphB2 depletion rescues cognitive functions in Alzheimer model. Nature 469, 47-52
23. Gardoni, F., Schrama, L. H., Kamal, A., Gispen, W. H., Cattabeni, F., and Di Luca, M. (2001) Hippocampal synaptic plasticity involves competition between Ca2/calmodulin-dependent protein kinase II and postsynaptic density 95 for binding to the NR2A subunit of theNMDAreceptor. J. Neurosci. 21, 1501-1509
24. Stravalaci, M., Beeg, M., Salmona, M., and Gobbi, M. (2011) Use of surface plasmon resonance to study the elongation kinetics and the binding properties of the highly amyloidogenic Aβ(1-42) peptide, synthesized by depsi-peptide technique. Biosens. Bioelectron. 26, 2772-2775
25. Stravalaci, M., Bastone, A., Beeg, M., Cagnotto, A., Colombo, L., Di Fede, G., Tagliavini, F., Cantù, L., Del Favero, E., Mazzanti, M., Chiesa, R., Salmona, M., Diomede, L., and Gobbi, M. (2012) Specific recognition of biologically active amyloid-β oligomers by a new surface plasmon resonance-based immunoassay and an in vivo assay in Caenorhabditis elegans. J. Biol. Chem. 287, 27796-27805
26. Saeed, S. M., and Fine, G. (1967) Thioflavin T for amyloid detection. Am. J. Clin. Pathol. 47, 588-593
27. Reinke, A. A., and Gestwicki, J. E. (2011) Insight into amyloid structure using chemical probes. Chem. Biol. Drug Des. 77, 399-411
28. Biasini, E., Turnbaugh, J. A., Unterberger, U., and Harris, D. A. (2012) Prion protein at the crossroads of physiology and disease. Trends Neurosci. 35, 92-103
29. Guillot-Sestier, M. V., Sunyach, C., Druon, C., Scarzello, S., and Checler, F. (2009) The α-secretase-derived N-terminal product of cellular prion, N1, displays neuroprotective function in vitro and in vivo. J. Biol. Chem. 284, 35973-35986
30. Guillot-Sestier, M. V., Sunyach, C., Ferreira, S. T., Marzolo, M. P., Bauer, C., Thevenet, A., and Checler, F. (2012) α-Secretase-derived fragment of cellular prion, N1, protects against monomeric and oligomeric amyloid-β (Aβ)-associated cell death. J. Biol. Chem. 287, 5021-5032
31. Selkoe, D. J. (2011) Resolving controversies on the path to Alzheimer's therapeutics. Nat. Med. 17, 1060-1065
32. Panza, F., Frisardi, V., Solfrizzi, V., Imbimbo, B. P., Logroscino, G., Santamato, A., Greco, A., Seripa, D., and Pilotto, A. (2012) Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies. Immunotherapy 4, 213-238
33. Alfa Cissé, M., Louis, K., Braun, U., Mari, B., Leitges, M., Slack, B. E., Fisher, A., Auberger, P., Checler, F., and Vincent, B. (2008) Isoform-specific contribution of protein kinase C to prion processing. Mol. Cell. Neurosci. 39, 400-410
34. Resenberger, U. K., Harmeier, A., Woerner, A. C., Goodman, J. L., Müller, V., Krishnan, R., Vabulas, R. M., Kretzschmar, H. A., Lindquist, S., Hartl, F. U., Multhaup, G., Winklhofer, K. F., and Tatzelt, J. (2011) The cellular prion protein mediates neurotoxic signalling of β-sheet-rich conformers independent of prion replication. EMBO J. 30, 2057-2070